Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has dipped nearly 5% in the last week after the company reported a Q2 earnings loss of $0.80....
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.
You...
On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and...
